Skip to main content
IBRX logo

IBRX · ImmunityBio, Inc.

Track IBRX — free
$6.02 -0.55 (-8.37%) At close · Nov 20
Market Cap
$6.40B
Shares
1.06B
Volume · Nov 20 10.64M Avg daily vol (3M) 12.89M

Price & Indicators

 

Key stats

Close
$6.02
Fri 20 Nov
Open
$6.41
Fri 20 Nov
Average volume, 30 days
14.1M
shares a session
Short interest
126.1M
11.9% of shares · 10.8 days to cover
Day range
$6.00$6.53
Open $6.41 Close $6.02
52-week closing range
$1.98$11.55
Close $6.02 47.9% under the high
Short volume, last session
58%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

May 6, 2027 Est · unconfirmed · in 24 wks
call held Jan 15, 2026

Latest documents

2026
Nov 19
Investor event
Anctiva Wins FDA Papillary-Only Approval; BCG-Naive Filing Due This Year

Third-quarter sales were nearly $49 million, up about 53% year over year, with about $144 million in sales for the first nine months. The FDA approved Anctiva at the end of October for BCG-unresponsive papillary-only bladder cancer. A BCG-naive trial met its endpoint with a p-value of 0.01, and a supplemental application is to be submitted this year.

8 source passages
we saw a nearly $49 million quarter, about a 53% growth year over year about almost $144 million in sales for the first nine months of the year we're going to get it. We're just not done. what they appreciate about Anctiva is the long duration of response we got it, let's just say at the end of October, to make it simple we now have the entire BCG unresponsive trial met its endpoint, but it has a p-value of 0.01 we will submit our BCG, the SBLA for BCG NAIVE yet this year Open the document at this passage
Nov 16
Investor event
BCG-naive endpoint met; SBLA submission planned this year

ImmunityBio said its BCG-naive trial met its endpoint with a p-value of 0.01 and plans to submit the SBLA this year; a recent approval expanded its label to papillary-only bladder cancer.

4 source passages
So the first thing is I'm happy to tell you today that, which we did not previously report out, that trial met its endpoint, but it has a p-value of 0.01. Is that we are on track to submit the SBLA this year. And because our first label that we have is the smallest part of bladder cancer, cis plus or minus, and end of October, plus or minus, is when we actually received, and we're the first in the world to actually receive this, our first in the United States to receive this, we now have the entire BCG unresponsive. So, CIS plus and minus papillary alone, and that's really a very important piece because if you look at that, and it's somewhere between two to three or four times larger market. And so as we sit here today, ImmunityBio is the IND holder for that 1,000-patient trial, and we've now converted it over. Open the document at this passage
Nov 16
Investor event
Anctiva BCG-naive trial met endpoint with BLA submission on track

ImmunityBio said Anctiva plus BCG met the endpoint in a BCG-naive bladder cancer trial, reporting a p-value of 0.01 and remaining on track to submit the BLA by the end of this year.

2 source passages
We have met the endpoint. We announced that. And most importantly, the p-value was 0.01. our intent was to submit it, the BLA or the SBLA, by the end of this year. And I'm happy to report today that we're completely on track with that. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ANKTIVA label expands as Q3 revenue grows 53%

ImmunityBio reported ANKTIVA’s October 14, 2026 FDA approval for BCG-unresponsive NMIBC with high-grade papillary-only tumors and Q3 2026 net product revenue of $48.7 million, up 53% year-over-year.

Revenue $48.84M ▲ 52.3% Net loss $184.55M Diluted EPS -$0.18
Read from the MD&A section
3 source passages
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. On October 14, 2026, the FDA approved our sBLA expanding the approved indication for ANKTIVA in combination with BCG to include adult patients with BCG-unresponsive NMIBC. This expanded indication now includes adult patients with BCG-unresponsive NMIBC with high-grade papillary-only tumors. Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, driven by continued adoption among U.S. urologists and strong market access Open the document at this passage
Nov 9
Current report 8-K
ANKTIVA Revenue Grows 53% as Label Expands

ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year; FDA expanded ANKTIVA’s indication for BCG-unresponsive NMIBC, and Israel approval brought global approvals to 35.

Financial results
3 source passages
Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, driven by continued adoption among U.S. urologists and strong market access FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved indication for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). ANKTIVA Approval in Israel: In November 2026, we announced approval in Israel of ANKTIVA in combination with BCG for BCG-unresponsive NMIBC with CIS, with or without papillary tumors, bringing the number of global approvals to 35. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$182.57M
Trailing 12 months
Net income (TTM)
−$1.11B
Trailing 12 months
Revenue growth YoY
+52.3%
Year over year
Operating margin
-150.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$380.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.1%
Year over year · more shares
Price change (1Y)
+198.0%
Trailing year
Short interest
11.9%
Latest settlement · 10.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −29%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 42%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −27%
trailing
6-month return −17%
trailing
YTD return +204%
this year
Relative strength −8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+0% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.85% of shares out · ▲ +2.6% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
416 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Strong
Revenue growth +668%
Y/Y
EPS growth +39%
Y/Y
Free cash flow $-308.8M
Buyback $18.3M
remaining
Quant / Vol
risk profile
Very High
Volatility 110%
annualized · 1-yr
Max drawdown −48%
past year
ATR 10.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
42% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+0% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.85% of shares out · ▲ +2.6% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
416 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $6 · 42% Range high $12
vs 200-day avg -25% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash and cash equivalents, and marketable securities $334.3M As of September 30, 2026 —
Revenue from top four customers (share of total gross revenue) 98% the three months ended September 30, 2026 filing —
Warrant exercises 6,399,171 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IBRX
ImmunityBio, Inc.
this stock
$6.40B +204.0% +668.3% — 11.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
416
% held
19.5%
Net QoQ
+5.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
202
View
Short & Settlement
Short Interest Rising
Shares short
126.1M
Days to cover
10.8d
Change
+3.1M sh
View
Short Volume
Short vol %
58%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
8.0K
Value
$69.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
52.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Sep 30, 2026
View
Financials
Financials
Revenue (FY)
$113.3M
Net income (FY)
$-351.4M
EPS diluted
$-0.38
View
Buybacks
Authorized
$50.0M
Remaining
$18.3M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 19, 2026
This year
27

Third-quarter sales were nearly $49 million, up about 53% year over year, with about $144 million in sales for the first nine months. The FDA approved Anctiva at the end of October for BCG-unresponsive papillary-only bladder cancer. A BCG-naive trial met its endpoint with a p-value of 0.01, and a supplemental application is to be submitted this year.

View
Proposed Sales
Value
$7.7M
Shares
560.0K
Filed
Oct 5, 2026
View
Exempt Offerings
Offering
$470.0M
Filed
Sep 22, 2023
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
ImmunityBio Named No. 2 Fastest-G…
Published
Nov 19, 2026
Upcoming events
6
View

Performance

5D 20D 120D MTD YTD
IBRX +0.0% -26.8% -16.7% -27.4% +204.0%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +8.6% -17.5% -7.6% -18.7% +202.9%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$50.00M
Spent (derived)
$31.70M
Remaining
$18.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1326110 CUSIP 45256X103 13F (30d) 377 filings 347 filers Visit website Investor relations